Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, open-label, phase I/II study investigating pharmacokinetic properties of BT524 and efficacy and safety of BT524 in the treatment and prophylaxis of bleeding in patients with congenital fibrinogen deficiency

Trial Profile

A prospective, open-label, phase I/II study investigating pharmacokinetic properties of BT524 and efficacy and safety of BT524 in the treatment and prophylaxis of bleeding in patients with congenital fibrinogen deficiency

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fibrinogen (Primary)
  • Indications Afibrinogenaemia; Congenital disorders; Haemorrhage
  • Focus First in man; Pharmacokinetics
  • Sponsors Biotest AG
  • Most Recent Events

    • 24 Jul 2019 Planned End Date changed from 1 Oct 2018 to 1 Nov 2020.
    • 24 Jul 2019 Planned primary completion date changed from 1 May 2018 to 1 Mar 2020.
    • 15 Mar 2018 According to a Biotest AG media release, the results of this and another study (700288385) will serve as a basis for the marketing authorisation of fibrinogen concentrate BT524 for treatment of patients with congenital and acquired fibrinogen deficiency.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top